Genentech, Inc. is a U.S.-based biotechnology company and member of the Roche Group, focused on the discovery, development, and manufacture of biologic medicines. Founded in 1976 and headquartered in South San Francisco, California, the company is known for early contributions to recombinant DNA technology and monoclonal antibody therapeutics.
Genentech’s portfolio and pipeline span oncology, immunology, neuroscience, ophthalmology, hematology, and infectious diseases. The company operates integrated R&D and cGMP biomanufacturing across multiple sites, with capabilities in large-scale mammalian cell culture, purification, and sterile fill-finish, supported by process development, analytical sciences, and quality operations. Within Roche’s global network, Genentech manages clinical and commercial supply of several biologics, including bevacizumab, trastuzumab, rituximab (with partners), atezolizumab, ocrelizumab, tocilizumab, omalizumab, and ranibizumab. The company emphasizes advanced bioprocessing, automation, and data-driven manufacturing to support reliable supply and regulatory compliance.
